Also found in: Medical.
CDERCenter for Drug Evaluation and Research (US FDA)
CDERCenter for Drug Evaluation and Research (Food and Drug Administration; Maryland)
CDERCentre de Développement des Energies Renouvelables (French)
CDERComputer Data Entry Recorder
CDERCentre de Developpement des Energies Renouvables (French)
CDERCentre for Diabetes and Endocrinology Research (Queensland, Australia)
CDERClient Development and Evaluation Report (California Department of Developmental Services)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Le Directeur du CDER a lors de sa presentation du bilan de 2018 a rappele que [beaucoup moins que] durant l'annee ecoulee, des conventions de cooperations scientifiques et techniques nationales et internationales ont ete signees dont celle etablis avec l'Institut coreen de technologies electroniques (KETI) [beaucoup plus grand que].
The number of new molecular entities (NMEs) and biologies approved by CDER beat the previous record of 53 in 1996 and was a substantial increase over the 46 new drugs approved in 2017.
is the Director of Professional Affairs and Stakeholder Engagement (PASE) at the Center for Drug Evaluation and Research (CDER) for the U.S.
CDER launched the DataFit project in 2011 with the goal of enabling its reviewers to rapidly assess whether submitted data was "fit for use" - to make the submission process more efficient and help get important new drugs to market safely and more quickly.
Table 1 is an overview of the enforcement activities of FDA's CDER division (Center for Drug Evaluation and Research).
In the draft guidance document CDER created a list (included as Appendix A in the guidance) of CMC changes they felt may be appropriate for inclusion in the annual report.
"These new regulations will help the FDA adopt a more consistent and neutral way of conveying information to a company when we cannot approve a drug application in its present form," said Janet Woodcock, M.D., director of CDER. "Thorough and timely review of drug applications is a priority of the FDA, and these new processes will make our communications with sponsors of applications more consistent."
Renata Albercht, director of the division of special pathogen and transplant products at CDER.
He was successful in assisting sponsors in filing Investigational New Drug (IND) applications for heterogeneous botanical products with the FDA Center for Drug Evaluation and Research (CDER).
The afternoon session featured presentations by the director and associate director of the new Office of Nonprescription Products in the Center for Drug Evaluation and Research (CDER) who provided their perspectives on overall CDER priorities and FDA policies and the OTC monograph process.
The database was developed by incorporating the FDA's Center for Drug Evaluation and Research (CDER) data, along with consumer information sheets, medical guides, and other information.
The center most involved in the approval process of HIV-related drugs is the Center for Drug Evaluation and Research (CDER).